Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H20F4N2O2 |
Molecular Weight | 408.3893 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC(=CC=C1)N(CC2=CC(F)=C(F)C(F)=C2)C(=O)O[C@H]3CN4CCC3CC4
InChI
InChIKey=UXZDMXYRRQJIBJ-IBGZPJMESA-N
InChI=1S/C21H20F4N2O2/c22-15-2-1-3-16(10-15)27(11-13-8-17(23)20(25)18(24)9-13)21(28)29-19-12-26-6-4-14(19)5-7-26/h1-3,8-10,14,19H,4-7,11-12H2/t19-/m0/s1
Tarafenacin (also known as SVT-40776) was developed as muscarinic M3 receptor antagonist for the treatment of overactive bladder. The drug participated in phase II clinical trial in patients suffering from overactive bladder, where both dose levels of tarafenacin were well tolerated. However, information about the further development of tarafenacin is not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21524581 |
1.5 nM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation. | 2012 Jan 12 |
|
Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. | 2014 Oct |
|
The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study. | 2015 Feb |
|
Current and future pharmacotherapy for treating overactive bladder. | 2016 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01458197
Tarafenacin 0.2 mg and Tarafenacin 0.4 mg
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
25147683
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
DTXSID301319099
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1779046
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
C87644
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
300000037038
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
LDV98UN52Y
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
385367-47-5
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
9065
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY